Credits Available: 4.75 hours of AMA PRA Category 1 Credit™; ABIM MOC

Description: Despite significant advancements in treatment, multiple myeloma remains an incurable disease, and nearly all patients experience relapse, often requiring increasingly complex therapeutic strategies.

With the rapid expansion of treatment options, particularly novel targeted therapies such as GPRC5D-directed approaches, the landscape of relapsed/refractory multiple myeloma (RRMM) management is evolving at an unprecedented pace. While these agents offer deep and durable remissions, their integration into clinical practice presents challenges in sequencing, toxicity management, and multidisciplinary coordination.

This educational initiative is designed to empower clinicians with the latest insights on GPRC5D-targeted therapies, facilitate the exchange of real-world clinical experience, and provide actionable strategies for optimizing patient outcomes. Through interactive discussions and expert-led guidance, participants will gain practical knowledge to navigate the complexities of RRMM treatment while fostering collaborative networks to enhance long-term patient care.

Join us to stay at the forefront of innovation in multiple myeloma management and elevate your clinical practice.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Nurse, Physician Associate/Assistant
Target Specialties: Hematology, Hematology/Oncology, Oncology

Christopher Ferreri

Atrium Health Wake Forest Baptist - Levine Cancer Institute
Clinical Assistant Professor

Dr. Ferreri is board certified in internal medicine, hematology, and medical oncology. Conditions he treats include plasma cell disorders, monoclonal gammopathy of undetermined significance, light chain amyloidosis, Waldenstrom macroglobulinemia (a blood cell cancer) and multiple myeloma.

Dr. Ferreri is a clinical assistant professor in the Department of Hematologic Oncology and Blood Disorders at Atrium Health Levine Cancer Institute. His research focuses on clinical and translational research involving multiple myeloma and CAR T-cell therapy. He has authored multiple publications and presented at conferences relating to CAR T-cell therapy for multiple myeloma.

Dr. Ferreri has received an American Society of Hematology (ASH) Abstract Achievement Award and an International Myeloma Society (IMS) Young Investigator Award.

He received his bachelor’s degree in molecular genetics and his medical degree at The Ohio State University. He completed residency at Duke University and a fellowship at The University of Texas MD Anderson Cancer Center, where he was named LBJ Oncology Clinical Fellow of the Year.

Outside of work, he is an avid sports fan who enjoys restaurants and the Blue Ridge Mountains. He loves spending time with his wife, family, friends and dog, a Cavapoo named Benny.